Introduction

Hyperuricemia frequently is associated with hypertension and hyperlipidemia that are risk factors for cardiovascular disease (1-3). For many years, it has been discussed whether or not hyperuricemia itself is a risk factor for cardiovascular diseases. Large-scale investigations have recently demonstrated that hyperuricemia is a risk factor for cardiovascular disease especially in hypertensive patients (4, 5). In recent years, it has been reported that some antihypertensive agents such as losartan, an angiotensin II receptor blocker, also lower the serum concentration of uric acid. The Losartan Intervention For Endpoint reduction in hypertension (LIFE)
study demonstrated the superiority of a losartan-based regimen over an atenolol-based regimen regarding cardiovascular morbidity and mortality. The LIFE study results were partly attributed to the lowering effect of losartan on the serum concentration of uric acid (6) .
Since approximately 1980, fenofibrate, a fibrate-type antihyperlipidemia drug, has been reported to decrease the serum concentration of uric acid via an enhanced urinary excretion of uric acid (7, 8) , but the detailed mechanism has remained unclear. Recently, Enomoto et (9) . It is important to clarify the precise mechanism of the urate lowering effect of lipid lowering agents used to treat patients with hyperlipidemia complicated with hyperuricemia.
al identified URAT1 as the transporter for uric acid reabsorption from the renal proximal tubules, and demonstrated that this is the target molecule of uric acid-lowering drugs like benzbromarone
In this study, we attempted to identify the mechanism of fenofibrate action on the renal excretion of uric acid and to clarify the role of fenofibric acid, the major active metabolite of fenofibrate, in healthy subjects. We also investigated the effect of fenofibrate on URAT1 in URAT1-expressing F i g u r e 3 . Ch a n g e s i n x a n t h i n e ( P X) , h y p o x a n t h i n e ( P HX) , f r a c t i o n a l e x c r e t i o n o f x a n t h i n e ( F E X) , f r a c t i o n a l e x c r e t i o n o f h y p o x a n t h i n e ( F E HX) , u r i n a r y e x c r e t i o n o f x a n t h i n e ( UXV) a n d u r i n a r y e x c r e t i o n o f h y p o x a n t h i n e ( UHXV) a f t e r t h e a d mi n i s t r a t i o n o f f e n o f i b r a t e . Fig. 1-A) (Fig. 1-B) , but uric acid clearance ( Fig. 1-C) and the fractional excretion of uric acid (Fig. 1-D (Fig. 1-E) 
Methods
* Plasma concentration of fenofibric acid
The plasma concentration of fenofibric acid increased reaching 4.7±1.8 μg/mL at 3 h and 8.5±1.0 μg/mL (maximum level) at 6 h followed by decrease to 5.8±0.6 μg/mL at 10 h after the administration (Fig. 2) . (Fig. 3-A) . Figure 3 o f i b r i c a c i d , r e d u c e d f e n o f i b r i c a c i d , b e n z b r o ma r o n e , a n d l o s a r  t a n o n u r i c a c i d u p t a k e v i a Ur a t e T r a n s p o r t e r 1 ( URAT 1 ) .
* Plasma concentration of xanthine and hypoxanthine
The plasma concentration of xanthine (PX) increased from 3 h after the administration and a significant difference was observed at 10 h after the administration: It was 0.16± 0.03 μg/mL at 0 h, 0.19±0.02 μg/mL at 6 h, and 0.26±0.02 μg/mL at 10 h after the administration. The plasma concentration of hypoxanthine (PHX) similarly increased from 3 h after the administration: It was 0.53±0.07 μg/mL at 0 h, 0.72±0.07 μg/mL at 6 h, and 0.93±0.08 μg/mL at 10 h after the administration
-B shows the fractional excretion of xanthine and hypoxanthine after the administration of fenofibrate [FEX (Cx/CCr) and FEHX (CHX/CCr)]. The fractional excretion of xanthine was slightly increased at 0 to 2 h, thereafter it decreased from 30.3±6.3% at 0-2 h to 9.6±1.3% at 4 to 8 h and 7.4±1.0% at 8 to 12 h showing a statistically significant difference with the value at 0-2 h. The fractional excretion of hypoxanthine decreased from 16.4±2.1% at -2 to 0 h to 10.2±1.4% at 0 to 2 h, 3.2±0.6% at 4 to 8 h, and 2.3±0.4% at 8 to 12 h. The decrease from 2 h after the administration was significant. The urinary excretion of xanthine and hypoxanthine (UXV and UHXV, respectively) per min were respectively 6.5±1.4 μg/min and 13.7±2.6 μg/ at -2 to 0 h followed by a
F i g u r e 4 . I n h i b i t o r y e f f e c t o f f e n
Inhibitor (µ M)
Fenofibric acid reduced fenofibric acid losartan benzbromarone (Fig. 3-C ).
Study 2: Effect of fenofibric acid on URAT1
As shown in Fig. 4 
Discussion
Gout and hyperuricemia were associated with hyperlipidemia in as high as approximately 50% of the cases (1-3). As for the type of underlying hyperlipidemia, the frequency of type IV hyperlipidemia is high at 60% to 70%, and the frequency of hypertriglyceridemia is thought to be high (3). The present results and the data reported in the literature clearly indicate that fenofibrate reduces serum uric acid via an increase of urinary excretion of uric acid, a mechanism that differs from that of lipid-lowering drugs. The mechanism of action of fenofibrate has not, however, been examined in detail.
The result of Study 1 showed that uric acid clearance began to increase immediately after the administration of fenofibrate and at 4 to 8 h after the administration it attained the maximum value, which was approximately 2.5-fold the level at baseline. The decrease of serum uric acid levels concomitant with the increase of uric acid clearance indicates that fenofibrate reduces serum uric acid levels by enhancing the urinary excretion of uric acid, as previously reported (7, 8) .
Fenofibrate is rapidly converted to its active metabolite fenofibric acid, and its reduced metabolite, reduced fenofibric acid, after absorption in humans. The major metabolites are fenofibric acid in blood and fenofibric acid, reduced fenofibric acid and their glucuronides in urine (11) . Fenofibric acid is thought to enhance the catabolism of triglycerides by increasing LPL activity via the activation of its nuclear receptor, i.e., the peroxisome proliferator-activated receptor α (PPARα), and by inhibiting the expression of apo C-III; thereby fenofibrate lowers the blood concentration of triglycerides (12) (13) (14) .
Based on many physiological experiments, human renal transport of uric acid was previously explained by the theory of four components consisting of glomerular filtration, proximal reabsorption and secretion, and reabsorption after secretion (15) . To date, the effect of benzbromarone on serum uric acid had been ascribed to the inhibition of reabsorption after secretion (16) . However, since URAT1 was identified as the uric acid transporter, it became clear that benzbromarone and losartan enhance the excretion of uric acid by inhibiting the reabsorption of uric acid via URAT1 (9) . Like fenofibrate, losartan decreases serum uric acid by enhancing the excretion of uric acid after single and repeated doses (17, 18) . As shown in Fig. 4 
